Company intelligence / Profile preview

Starpharma

Abbotsford* / Melbourne*, Victoria, Australia

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Starpharma has commercialized several dendrimer-based products such as VivaGel BV, VivaGel Condom, and VIRALEZE Nasal Spray. Its DEP® oncology candidates have advanced through early to mid-stage clinical trials with over 350 patients treated. The company’s technology has demonstrated improved drug delivery characteristics and reduced toxicity in preclinical and clinical settings.

Therapeutic areas: Infectious DiseasesWomen's HealthOncology
Modalities: Polymer-drug conjugate therapySmall moleculeAntimicrobial agent
Industry: Biotech

Drug pipeline

7 assets

astodrimer

6 more assets in the full pipeline.

Request access →

Partnerships

AstraZeneca (DEP platform licensing)Medicxi/Petalion Therapeutics Limited co-founding partnershipITROM Pharmaceutical Group distribution agreement

Beyond the preview

Go deeper on Starpharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Starpharma.

Explore the full profile